Sandoz Challenges Amgen’s $3.3B Arthritis Drug Monopoly in U.S. Antitrust Lawsuit
Swiss pharmaceutical company Sandoz has initiated a legal battle against U.S. biotech giant Amgen, accusing it of unlawfully maintaining a monopoly over the arthritis medication Enbrel (etanercept). Filed in a federal court in Norfolk, Virginia, the lawsuit alleges that Amgen has employed a “thicket of patents” to block competition from biosimilars, including Sandoz’s Erelzi, effectively extending its market dominance through 2029.
Despite receiving FDA approval for Erelzi in 2016, Sandoz claims it has been unable to enter the U.S. market due to Amgen’s patent strategies. The company argues that this has resulted in billions of dollars in profits for Amgen while denying patients access to more affordable alternatives. In 2024 alone, Enbrel generated $3.3 billion in U.S. revenue.
Sandoz is seeking an injunction to lift the patent barriers and is also requesting financial damages. Amgen has yet to respond to the lawsuit.
2026-10-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
INEOS Closes US Polystrene Plant: 400K Tons of PD in the US Can't Hold On
-
Lotte Merges with HD Hyundai: Can Korea’s Petrochemical First Case Trigger True Restructuring?
-
Evonik Cuts 3,200 Jobs: Europe’s Chemical Winter Is Not Over
-
As Middle East Supply Faces Disruptions, SABIC's 1.8 Million Mt/Year Methanol New Project Secures Saudi Feedstock Quota
-
South Korea Moves Urgently to Control Petrochemical Feedstock Hoarding as Supply Chain Risk Escalates to the National Security Level
-
Dow Swings from an $801 Million Loss to an $802 Million Profit as Hormuz Disruption Lifts Polyethylene Prices
-
Türkiye Advances $3 Billion Petrochemical Cluster Targeting 17% of Domestic Polypropylene Demand
-
Argentina to Build Latin America’s Largest Urea Plant Under €1.3 Billion Contract
-
Hormuz Crisis Pushes Up Urea Prices as Yara’s Quarterly EBITDA Jumps 39%
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
Recommend Reading
-
BorsodChem Raises MDI Prices by €500 as Cost Pressure in Europe’s Polyurethane Chain Continues to Escalate
-
BASF Raises BA and 2-EHA Prices as Acrylic Ester Costs Continue to Move Higher in Asia-Pacific
-
LANXESS Raises Global 1,6-Hexanediol Prices by 20% as Cost Pressure Begins to Pass Downstream
-
Novo Nordisk Faces a Compliance Test
-
Deméter Enters China with a Stress-Focused Pitch
-
Business Society October 16, 2026 Acetic Acid Trend Analysis: Clear Downtrend
-
Business Society October 16, 2026 Iso-octanol Trend Analysis: Strongly Bullish
-
Business Society October 15, 2026 BDO Trend Analysis: High-Level Volatility
-
Business Society October 16, 2026 Acrylic Acid Trend Analysis: Volatility
-
Business Society, October 15, 2026: Fuel Oil 180CST Trend Analysis – Volatility
- Hot Searches
- where do i get retatrutide
- aluminum cholride
- peptides company
- aeo 7 surfactant
- is miconazole nitrate the same as miconazole
- na-931 for sale
- high density polyethylene price
- myclobutanil market
- enterobacter cloacae complex treatment
- benzoicane
- retatrutide peptide buy usa price
- methylene blue wikipedia